Research advances in adverse liver reactions caused by immune checkpoint inhibitors
10.3969/j.issn.1001-5256.2022.01.039
- VernacularTitle:免疫检查点抑制剂所致肝脏不良反应的研究进展
- Author:
Yu WANG
1
;
Zhaoying LI
2
;
Shuang LI
1
;
Chenghai LIU
3
,
4
Author Information
1. Department of Gastroenterology, Baoshan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 201999, China
2. Department of Neurology, The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610000, China
3. Second Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
4. Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
- Publication Type:Reviews
- Keywords:
Chemical and Drug Induced Liver Injury;
Immunosuppressive Agents;
Therapeutics
- From:
Journal of Clinical Hepatology
2022;38(1):220-223
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors can enhance the anti-tumor effect of T cells by blocking the negative regulatory signal of T cells, and meanwhile, they may also cause the imbalance of immune tolerance or normal immune hyperfunction, thus leading to immune hepatitis. This article mainly reviews the therapeutic mechanism of immune checkpoint inhibitors, their mechanism in causing the adverse reaction of liver injury, related risk factors, and incidence rate and summarizes the treatment methods for liver injury caused by immune checkpoint inhibitors. It is believed that while promoting anti-tumor immunity, immune checkpoint inhibitors may cause non-homogeneous immune-related liver injury due to the specificity of non-tumor tissue targets, and the main purpose of treatment is to restore immune homeostasis. Therefore, the management of patients using immune checkpoint inhibitors often requires a balance between treatment window, toxicity, and treatment of specific injury, as well as multidisciplinary collaboration.
